Saturday, April 25


Barcelona: Leading medical journal The Lancet will decline a request to provide evidence for a U.S. Senate inquiry into the origins of the COVID-19 pandemic, its editor-in-chief Richard Horton told Reuters in an interview on Friday.

“We have received a request to go and give evidence at ‌a Senate inquiry, which ⁠we’re ⁠not going to do,” Horton told Reuters at the Reuters Pharma event in Barcelona.

Horton ​said that the journal would not engage “with an administration that has attacked some ​of the foremost scientists of our age”, citing the treatment by President Donald Trump’s administration of a former top U.S. health official, Anthony Fauci, who ​led the country’s COVID-19 response.

He has faced ⁠threats since ‌then as well as the ire of Trump and ​fellow Republicans. ​Trump cancelled Fauci’s federal security protection last year.

Horton wrote ⁠in February that the Lancet had been asked in December ​2025 to provide all records relating to coronaviruses from ​2018 to 2022, including emails, notes and studies. The journal Science was asked the same thing, according to a story on its website.

Horton was referring to an inquiry by U.S. Senator Rand Paul, who has been looking into U.S. funding provided to a virology lab in ‌Wuhan, China, the city where the Covid-19 pandemic began in 2020. Paul chairs the Homeland Security and Governmental Affairs ​Committee.

Paul’s office ​did not immediately respond ⁠to a request for comment.

“They’re still perseverating over Wuhan and what took place there in the latter part of 2019,” Horton said.

The World Health ​Organization and most scientists say a spillover from nature is the most likely cause for the pandemic. Investigations have been hampered by a lack of data from China, but U.S. intelligence services said last year that a lab leak was probably the cause. (Reporting by Jennifer Rigby and Bhanvi Satija in Barcelona; Editing by David Gregorio)

  • Published On Apr 25, 2026 at 08:12 AM IST

Join the community of 2M+ industry professionals.

Subscribe to Newsletter to get latest insights & analysis in your inbox.

All about ETHealthworld industry right on your smartphone!




Source link

Share.
Leave A Reply

Exit mobile version